{"id":"W4404136502","doi":"10.1016/j.jtho.2024.10.026","title":"The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Santé Montérégie; McGill University; St Mary's Hospital Centre","funders":"Daiichi Sankyo Europe; EMD Serono; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; G1 Therapeutics; Pfizer; Coherus Biosciences; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Pemetrexed; Oncology; Maintenance therapy; Olaparib; Internal medicine; Lung cancer; Cancer; Chemotherapy; Immunotherapy; Polymerase; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001826192,0.001900796,0.003134833,0.0004585948,0.0004361685,0.001590145,0.001356385,0.00157599,0.00804512],"category_scores_gemma":[0.001106351,0.0008453666,0.002863876,0.0004139577,0.001235031,0.001523509,0.0005134169,0.006372525,0.001699519],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001642085,"about_ca_system_score_gemma":0.001887207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001944025,"about_ca_topic_score_gemma":0.006320444,"domain_scores_codex":[0.9995209,0.000215675,0.00002028466,0.00008499439,0.00003885308,0.0001192945],"domain_scores_gemma":[0.9994241,0.00009985226,0.0001046693,0.00004606792,0.00003279678,0.000292517],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8929449,0.01720157,0.001411323,0.001220636,0.002490559,0.00008438587,0.0001531471,0.002497476,0.01389282,0.0005104981,0.005632,0.06196069],"study_design_scores_gemma":[0.8296269,0.1586269,0.004702444,0.00005479519,0.001008496,0.0001149352,0.00006204675,0.001001526,0.001250904,0.0003717438,0.003143753,0.00003559065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765006,0.007031229,0.0008825384,0.002192369,0.00102259,0.002773504,0.003805722,0.0002684371,0.005522927],"genre_scores_gemma":[0.9734797,0.004888699,0.002492351,0.00240488,0.000434053,0.003112968,0.004382674,0.00009975804,0.008705024],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00804512,"threshold_uncertainty_score":0.02691358,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06874955987987083,"score_gpt":0.4853731063338285,"score_spread":0.4166235464539577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}